title: Differences in hemostasis among sclerosing agents in endoscopic injection sclerotherapy.
abstract: Endoscopic injection sclerotherapy is useful in stopping bleeding from esophageal varices. We compared the in vivo effects of sclerosants on thrombogenesis, hemostasis, and endothelial injury. We injected aethoxysclerol (AS) of ethanolamine oleate (EO) into the small veins of the rat intestine. The maximum thrombogenic index with AS was 30.7 and with EO was 9.2. The venous flow stopped sooner with EO than with AS. The thrombi caused by EO were mixed with red blood cells. Heparin pretreatment decreased the thrombogenic index with AS by 96.7%, but not that with EO. The area of the fluorescein-albumin conjugate that permeated from veins with AS was larger than that with EO. The fluorescent intensity with AS was lower than that with EO. We thus conclude that: (1) the size of thrombi is not necessarily proportional to the hemostatic efficacy; (2) change in a patient's coagulation may affect the potential of sclerosants; (3) the excellent hemostatic efficacy of EO is based on localized injury to the endothelium and the involvement of red blood cells aggregation; and (4) in vivo microscopy is useful in determining the rational selection of sclerosants.
authors.affiliation: Department of Internal Medicine, Saiseikai Central Hospital, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Tatemichi
authors.forename: H
authors.initials: H
authors.lastname: Nagata
authors.forename: E
authors.initials: E
authors.lastname: Sekizuka
authors.forename: T
authors.initials: T
authors.lastname: Morishita
authors.forename: M
authors.initials: M
authors.lastname: Miyairi
authors.forename: M
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: H
authors.initials: H
authors.lastname: Ishii
mesh_terms: D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D016099:Endoscopy, Gastrointestinal; D004730:Endothelium, Vascular / Q000187:drug effects; D016650:Fluorescein-5-isothiocyanate / Q000493:pharmacokinetics; D006487:Hemostasis / Q000187:drug effects; D006490:Hemostatics / Q000008:administration & dosage / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000098:blood supply; D008297:Male; D009829:Oleic Acids / Q000008:administration & dosage / Q000494:pharmacology; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000494:pharmacology*; D015911:Sclerotherapy / Q000379:methods*; D012710:Serum Albumin, Bovine / Q000493:pharmacokinetics; D013927:Thrombosis / Q000139:chemically induced; D014680:Veins
chemical_list: D006490:Hemostatics; D009829:Oleic Acids; D012597:Sclerosing Solutions; D000077423:Polidocanol; D012710:Serum Albumin, Bovine; D011092:Polyethylene Glycols; D016650:Fluorescein-5-isothiocyanate; C033343:ethanolamine oleate